Sanofi taps Leukocare for vaccine stabilization

Sanofi Pasteur says it will examine Leukocare's Stabilizing and Protecting Solutions technology to see whether the platform could help the vaccine developer improve the shelf-life of its vaccines, according to a report in Genetic Engineering News. Financial details of the deal were not disclosed.

Germany-based Leukocare's technology helps stabilize proteins during storage in dehydrated conditions and protects proteins to maintain biological activity during sterilization by gamma-, beta-radiation or ethylene oxide, according to the company's website. Improving the stabilization of vaccines make them safer and more effective. Sanofi didn't say which of its vaccines it would target using Leukocare's technology.

- here's the report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.